Fertility · PCOS
Myo-Inositol for PCOS and Fertility: Dose, Ratio, and Evidence
Myo-inositol is a B-vitamin-like sugar alcohol that acts as a second messenger for insulin and FSH signaling in the ovary. In women with PCOS — and in many TTC patients without a formal diagnosis — supplementing myo-inositol improves ovulatory cycles, egg quality, and insulin sensitivity. Here's the evidence and the dose that matters.
What myo-inositol actually is
Myo-inositol is a naturally occurring sugar alcohol, sometimes grouped with the B-vitamin family (historically called vitamin B8). Your body makes it endogenously, and you also take in ~1 g/day from a normal diet — beans, citrus, whole grains, buckwheat. Its biological job is to serve as a second-messenger precursor: cells convert myo-inositol into inositol triphosphate (IP3) and inositol phosphoglycans, which relay signals from receptors at the cell surface (FSH, insulin, TSH) to the machinery inside the cell.
In the ovary, myo-inositol is enriched in follicular fluid, and its concentration in that fluid correlates with oocyte quality. In insulin-signaling tissues (liver, muscle, adipose), it drives glucose uptake. Both of those pathways are disrupted in PCOS, which is why supplementation matters.
The mechanism, in plain terms
- FSH signaling in granulosa cells. Myo-inositol is a required second messenger for FSH's action on the maturing follicle. Deficiency correlates with poor oocyte quality and delayed maturation.
- Insulin signaling. Inositol phosphoglycans mediate a portion of insulin's downstream glucose transport. In insulin resistance (a core PCOS feature), inositol availability limits this pathway.
- Androgen production. By improving insulin sensitivity, myo-inositol lowers ovarian androgen production, restoring cycle regularity in PCOS patients.
Why the 40:1 ratio matters
Your body uses two inositol isomers — myo-inositol (MI) and d-chiro-inositol (DCI). In plasma, they exist at roughly a 40:1 ratio. That ratio is not arbitrary: MI is the FSH-signal messenger in the ovary, while DCI is the insulin-signal messenger in the liver and muscle. In the ovary, an excess of DCI relative to MI actually degrades oocyte quality — the so-called "DCI paradox" documented by Unfer and Nordio.
Products loaded with cheap DCI (some legacy "PCOS blends") worsen outcomes in normal-weight PCOS. The 40:1 MI:DCI ratio matches plasma physiology and has the strongest RCT support for both ovulation restoration and IVF outcomes. Any product that does not disclose its ratio, or advertises DCI as the primary ingredient, should be avoided.
Dosing and duration
- Standard PCOS/fertility dose: 2 g myo-inositol twice daily (4 g total), plus 50 mg d-chiro-inositol daily (the 40:1 ratio).
- Timing: With meals for GI tolerance. Some patients split into 1 g four times daily.
- Duration: Minimum 90 days before assessing cycle regularity; 3–6 months before IVF stimulation.
- Onset: Cycle regularity typically shifts by 2–3 months; metabolic markers (fasting insulin, HOMA-IR) improve at 8–12 weeks.
Evidence summary
The literature is remarkably consistent for a supplement:
- Pundir 2018 meta-analysis (n = 1472, 10 RCTs): significant improvement in ovulation and clinical pregnancy rate vs placebo in PCOS.
- Greff 2023 meta-analysis: improvements in HOMA-IR, fasting insulin, testosterone, and menstrual regularity comparable to metformin, with substantially fewer GI side effects.
- Unfer 2017: 40:1 MI:DCI ratio superior to DCI-only formulations for oocyte quality.
- Nordio 2019: confirmed 40:1 ratio superiority in normal-weight PCOS.
- Papaleo 2009, Ciotta 2011: improved IVF outcomes (fertilization rate, embryo quality) with pre-cycle inositol.
Who should take it
- Confirmed PCOS (Rotterdam criteria).
- Irregular cycles + elevated AMH suggesting PCOS phenotype.
- Insulin resistance / metabolic syndrome — even without formal PCOS.
- TTC patients with prior poor IVF response and evidence of oocyte quality issues.
- Gestational diabetes prevention (evolving evidence — discuss with clinician).
Contraindications and cautions
- Bipolar disorder. Very high-dose inositol (12–18 g/day) has been studied for mood disorders; interaction with lithium is possible. At fertility doses (4 g) risk is low but coordinate with psychiatry.
- Metformin co-use. Compatible and often synergistic, but combined GI side effects are common. Titrate one at a time.
- Pregnancy. Generally continued through the first trimester in high-risk PCOS pregnancies; discuss with your OB.
Where it fits in a TTC plan
For any patient with PCOS or insulin resistance, inositol is foundational — start it before or alongside CoQ10, prenatal, and clinical evaluation. Pair with a proper fertility panel and lifestyle intervention. If cycles remain irregular after 3 months of proper dosing, request a fertility consult to add letrozole/clomiphene or escalate.
Sources
- Pundir J, et al. Inositol treatment of anovulation in women with PCOS: meta-analysis. BJOG 2018.
- Greff D, et al. Inositol is an effective and safe treatment in PCOS: systematic review and meta-analysis. Reprod Biol Endocrinol 2023.
- Unfer V, et al. Myo-inositol effects in women with PCOS: meta-analysis. Endocr Connect 2017.
- Nordio M, et al. The 40:1 myo-inositol/d-chiro-inositol plasma ratio is able to restore ovulation. Eur Rev Med Pharmacol Sci 2019.
Related
Frequently asked questions
What ratio of myo to d-chiro inositol works?
The 40:1 myo-to-d-chiro ratio matches physiological plasma levels and is the ratio with the strongest PCOS evidence (Nordio 2019, Unfer 2017). kindr Egg Quality uses this ratio.
How much should I take?
Standard dosing is 2 g twice daily (4 g total) for at least 90 days before conception attempts or before an IVF cycle.
Does inositol work if I do not have PCOS?
Yes — benefits on oocyte quality and insulin sensitivity have been documented in non-PCOS IVF patients as well, though effects are largest in insulin-resistant phenotypes.
Can I take it with metformin?
They can be used together, but coordinate with your clinician — combining may amplify GI side effects.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-06-23. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.